Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris

Cheng, Jing; Su, Xing; Qiao, Lei; Zhai, Chao; Chen, Wenqiang

doi:10.1042/bsr20181099

Cited by 13 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study that investigated the role of FGF21 in SAP found higher FGF21 levels (SAP: 323.16 ± 434.66 vs. control: 266.46 ± 417.13 pg/mL; p = 0.039), similar to our study; however, multiple regression analyses showed that FGF21 levels could not be used as a marker for SAP (18). In another study, serum FGF21 levels were found higher in patients with unstable angina pectoris than in the SAP and control group, and there was no difference between serum FGF21 levels in SAP and control subjects un like to our study (19). This may be due to study design differences, heterogeneities in patients' cardiovascular risk profiles, insulin resistance, drug use, body mass index, visceral fat distribution, and gender distribution.…”

Section: Discussionsupporting

confidence: 88%

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Nar¹,

Sanlialp²,

Nar³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

Aim: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However, the studies which investigate the relationship between serum FGF21 levels and coronary artery disease (CAD) include conflicting data. In this study, we planned to investigate the role of FGF21 in CAD development and CAD severity. Method: Seventy-eight patients with stable angina pectoris (SA) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors who underwent coronary angiography were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results: Although there was a statistically significant difference between serum FGF21 levels in the SA and the control groups [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. The SA group had lower serum HDL-C levels (41.57 ± 11.40 vs. 54.90 ± 34.47; p = 0.02). There was a significant and negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusion: The serum FGF21 levels are different between SA diagnosed and control patients. FGF21 may be a marker for CAD diagnosis, but not for the evaluation of CAD severity. To the best of our knowledge, this is the first study to evaluate coronary artery disease severity together with a lipid profile.

show abstract

Section: Discussionsupporting

confidence: 88%

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Nar¹,

Sanlialp²,

Nar³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

“…Supplementary Table 1 summarizes the patient selection criteria of these studies. Among these studies, 14 reported serum FGF21 concentration in patients with or without CVDs ( 10 – 23 ), 14 reported ORs or HRs of serum FGF21 concentration and incidence of CVDs ( 11 , 14 , 17 , 18 , 20 , 24 – 32 ), 8 reported Pearson's r of serum FGF21 concentration and vascular parameters ( 12 , 15 , 16 , 25 , 30 , 33 – 35 ), and 6 reported incidence of CVDs in individuals with different serum FGF21 levels ( 27 , 30 , 36 – 39 ).…”

Section: Resultsmentioning

confidence: 99%

“…Three studies also provided serum FGF21 concentration of each patient in scatter plots ( 10 , 14 , 23 ) ( Supplementary Figure 1 ). Among 14 studies, 9 studies reported that serum FGF21 concentration was significantly higher in patients with CVDs, including CAD and hypertension ( 11 , 12 , 14 , 15 , 17 – 19 , 22 , 23 ). However, one study reported that serum FGF21 concentration was significantly lower in patients with subclinical atherosclerosis ( 13 ).…”

Section: Resultsmentioning

confidence: 99%

High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Zhang

Yan

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: The association between fibroblast growth factor 21 (FGF21) and cardiovascular disease (CVD) risk remains unclear. We conducted this systematic review and meta-analysis to evaluate the association between FGF21 and CVDs, and relevant vascular parameters.Methods: PubMed and Web of Science databases were systematically searched to identify relevant studies published before March 2021. The FGF21 concentration was compared between individuals with and without CVDs. The effect of FGF21 on CVD risk was assessed by using hazard ratio (HR) and odds ratio (OR). The association between FGF21 and vascular parameters was assessed by Pearson's r. Study quality was assessed using Newcastle–Ottawa Scale and Joanna Briggs Institution Checklist.Results: A total of 29,156 individuals from 30 studies were included. Overall, the serum FGF21 concentration was significantly higher in CVD patients (p < 0.001), especially for coronary artery disease (CAD) (p < 0.001) and hypertension (p < 0.001). The pooled OR (p = 0.009) and HR (p < 0.001) showed that the risk of CVDs increased with FGF21. The linear association between FGF21 and vascular parameters, including pulse wave velocity (r = 0.32), carotid intima-media thickness (r = 0.21), ankle-brachial index (r = 0.33), systolic blood pressure (r = 0.13), and diastolic blood pressure (r = 0.05), was insignificant. The incidence of overall CVDs (p = 0.03) was significantly higher in individuals with higher FGF21 levels.Conclusion: High-level serum FGF21 concentration is closely associated with an increased risk of CVDs, which may be independent of vascular parameters. A standard FGF21 classification threshold needs to be established before clinical use for CVD risk assessment.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=241968, identifier: CRD42021241968.

show abstract

“…The difference in admission values of FGF 21 between outcome groups (Table 1, Fig. 1) suggests faster elevation in the poor outcome group, although it may also partly reflect the cardiovascular risk factors preceding the cardiac arrest [28][29][30] . The association of higher FGF 21 concentrations during the first 72 h with poor 6-month outcome (Tables 3, 4, 5) suggest that the stressful process leading to FGF 21 expression fails to resolve in the poor outcome group.…”

Section: Or 95% CI P-valuementioning

confidence: 99%

“…Our findings are in line with previous data reporting elevated FGF 21 levels in general population of critical care patients 13 . The emerging role of FGF 21 as a marker of mitochondrial dysfunction 27 combined with reports of elevated FGF 21 predicting cardiovascular events [28][29][30] make cardiac arrest an especially interesting condition for studying FGF 21 due to the extreme ischaemia-reperfusion event of circulatory standstill followed by resuscitation.…”

Section: Or 95% CI P-valuementioning

confidence: 99%

Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome

Pekkarinen

Skrifvars

Lievonen

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Fibroblast growth factor (FGF) 21 is a marker associated with mitochondrial and cellular stress. Cardiac arrest causes mitochondrial stress, and we tested if FGF 21 would reflect the severity of hypoxia-reperfusion injury after cardiac arrest. We measured serum concentrations of FGF 21 in 112 patients on ICU admission and 24, 48 and 72 h after out-of-hospital cardiac arrest with shockable initial rhythm included in the COMACARE study (NCT02698917). All patients received targeted temperature management for 24 h. We defined 6-month cerebral performance category 1–2 as good and 3–5 as poor neurological outcome. We used samples from 40 non-critically ill emergency room patients as controls. We assessed group differences with the Mann Whitney U test and temporal differences with linear modeling with restricted maximum likelihood estimation. We used multivariate logistic regression to assess the independent predictive value of FGF 21 concentration for neurologic outcome. The median (inter-quartile range, IQR) FGF 21 concentration was 0.25 (0.094–0.91) ng/ml in controls, 0.79 (0.37–1.6) ng/ml in patients at ICU admission (P < 0.001 compared to controls) and peaked at 48 h [1.2 (0.46–2.5) ng/ml]. We found no association between arterial blood oxygen partial pressure and FGF 21 concentrations. We observed with linear modeling an effect of sample timepoint (F 5.6, P < 0.01), poor neurological outcome (F 6.1, P = 0.01), and their interaction (F 3.0, P = 0.03), on FGF 21 concentration. In multivariate logistic regression analysis, adjusting for relevant clinical covariates, higher average FGF 21 concentration during the first 72 h was independently associated with poor neurological outcome (odds ratio 1.60, 95% confidence interval 1.10–2.32). We conclude that post cardiac arrest patients experience cellular and mitochondrial stress, reflected as a systemic FGF 21 response. This response is higher with a more severe hypoxic injury but it is not exacerbated by hyperoxia.

show abstract

Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris

Cited by 13 publications

References 45 publications

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome

Contact Info

Product

Resources

About